Trademark: 97180459
Status Date
Wednesday, January 24, 2024
Filing Date
Monday, December 20, 2021
Published for Opposition
Tuesday, May 23, 2023
5 Pharmaceutical, medical and veterinary preparations and substances, namely, pharmaceutical preparations and substances for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemico-pharmaceutical preparations for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; biochemical preparations for medical use, namely, biochemical preparations for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer
42 Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological research, clinical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer, and medical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory services, namely, laboratory research services, medical laboratory services, scientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemical research and analysis services including analytical services relating to medicines, pharmaceutical preparations and biochemistry; research laboratories, namely, laboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological research, namely, cell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testing, namely, development and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studies, namely, technical research in the field of pharmaceutical studies; preparation of project analysis studies, namely, conducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products
The mark consists of the word "MOLECURE" in stylized font.
MOLE CURE
Color is not claimed as a feature of the mark.
Dec 23, 2021
New Application Entered
Dec 27, 2021
New Application Office Supplied Data Entered
Sep 7, 2022
Automatic Update Of Assignment Of Ownership
Sep 25, 2022
Assigned To Examiner
Oct 14, 2022
Non-Final Action Written
Oct 14, 2022
Non-Final Action E-Mailed
Oct 14, 2022
Notification Of Non-Final Action E-Mailed
Mar 27, 2023
Teas Response To Office Action Received
Mar 27, 2023
Correspondence Received In Law Office
Mar 28, 2023
Teas/Email Correspondence Entered
Apr 20, 2023
Examiners Amendment -Written
Apr 20, 2023
Examiners Amendment E-Mailed
Apr 20, 2023
Notification Of Examiners Amendment E-Mailed
Apr 20, 2023
Examiner's Amendment Entered
Apr 20, 2023
Approved For Pub - Principal Register
May 3, 2023
Notification Of Notice Of Publication E-Mailed
May 23, 2023
Published For Opposition
May 23, 2023
Official Gazette Publication Confirmation E-Mailed
Jul 18, 2023
Noa E-Mailed - Sou Required From Applicant
Jan 4, 2024
Teas Statement Of Use Received
Jan 23, 2024
Case Assigned To Intent To Use Paralegal
Jan 4, 2024
Use Amendment Filed
Jan 24, 2024
Statement Of Use Processing Complete
Jan 24, 2024
Su - Non-Final Action - Written
Jan 24, 2024
Non-Final Action E-Mailed
Jan 24, 2024
Notification Of Non-Final Action E-Mailed
Apr 24, 2024
Teas Response To Office Action Received
Trademark Alertz updated from USPTO on 2030-01-24
